Cyclo Therapeutics to Participate in the M-Vest Virtual Conference Series: Alzheimer’s Disease Panel
- Panel discussion around innovating Alzheimer's Disease ("AD") drug development on Wednesday, May 26th 11:00 AM ETGAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to...
Cyclo Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
- Pivotal Phase 3 study of Trappsol® Cyclo™ for Niemann-Pick Disease Type C (NPC) on track to commence enrollment and dosing in Q2 2021- Company advancing Alzheimer's Disease Phase 2 asset towards investigational new drug application (IND) filing...
Cyclo Therapeutics Appoints Lori McKenna Gorski as Global Head of Patient Advocacy
Ms. Gorski brings more than two decades of communications and patient advocacy experience serving rare disease communitiesFormerly led global communications and patient advocacy strategies for lysosomal storage disorders at Sanofi Genzyme GAINESVILLE, Fla. - Cyclo...
Cyclo Therapeutics Announces Design of Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1
Patient enrollment on track to commence in Q2 2021Global clinical protocol agreed with US Food and Drug Administration (FDA) and European MedicinesAgency (EMA)Dual primary objectives agreed; FDA 4-Domain Niemann-Pick disease Type C-Severity Scale (4D-NPC-SS) and EMA...
Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol® Cyclo™ in Alzheimer’s Disease
FDA feedback supports Company's Phase 2 development strategy for Alzheimer's disease asset; IND filing on track for H2 2021 GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company...
Cyclo Therapeutics Meets Primary Efficacy Endpoint in Phase 1/2 Trial from Intravenous Trappsol® Cyclo™ in Rare Disease Niemann-Pick Type C1 (NPC1)
100% of patients who completed the trial improved or remained stable, and 89% met the efficacy outcome measure of improvement in at least 2 domains of the 17-domain NPC Severity Scale Trial data suggest that Trappsol® Cyclo™ overcomes the NPC1 defect by...
Cyclo Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
- Multiple value-driving milestones expected throughout 2021- Trappsol® Cyclo™ Niemann Pick Disease Type C (NPC) clinical program on track to imminently report topline results from Phase 1/2 study- Company expects to commence enrollment in pivotal Phase 3...
Cyclo Therapeutics to Participate in Inaugural Emerging Growth Virtual Conference
Presenting Innovative Small and Mid-Cap Companies in Healthcare, Industrials, Electric Vehicles, TMT, and Consumer ProductsGAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company...
Cyclo Therapeutics Appoints Russ Belden as Acting Chief Commercial Officer
Preeminent biotechnology commercialization leader with over 33 years of industry experience, including 16 years at Genentech with a pivotal role in commercializing products across multiple therapeutic areasGAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH)...
Cyclo Therapeutics Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan for Trappsol® Cyclo™
GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease,...